PRODUCTS

PIPELINE

Amarin is progressing several development candidates for CNS and cardiovascular disease. The pipeline contains a mix of new chemical entities (NCEs) and improved outcome formulations of established drugs, all addressing unmet patient needs. To learn more above each program or indication select an item from the chart below.

Pipeline Parkinson’s disease EN101 Sublingual Apomorphine AMR101 Memory (AAMI) Nasal Lorazepam Huntington’s disease Myasthenia Gravis Parkinson’s disease Epilepsy Hypertriglyceridemia

*The pipeline chart does not display all research porgrams